Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

ABSTRACT:

Background

Early decrease in Ki67 after a short preoperative course of endocrine therapy (ET) has shown prognostic and predictive value in clinical research, but its applicability and reproducibility in routine clinical practice remain largely unknown. We therefore assessed on-treatment Ki67 changes following a short preoperative ET and its association with biological variables, such as intrinsic subtype and risk of recurrence (ROR), plus long-term outcomes, in a real-world cohort of patients with early estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-negative) breast cancer.

Methods

We conducted a retrospective, registry-based analysis of 230 consecutive patients with early ER+/HER2- breast cancer treated as per standard clinical care

SUBMITTER: Gomez-Bravo R 

PROVIDER: S-EPMC12554025 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature